Zahra Mansouri, Yazdan Salimi, Ghasem Hajianfar, Luisa Knappe, Nicola Bianchetto Wolf, Genti Xhepa, Adrien Gleyzolle, Alexis Ricoeur, Valentina Garibotto, Ismini Mainta, Habib Zaidi
{"title":"Potential of Radiomics, Dosiomics, and Dose Volume Histograms for Tumor Response Prediction in Hepatocellular Carcinoma following <sup>90</sup>Y-SIRT.","authors":"Zahra Mansouri, Yazdan Salimi, Ghasem Hajianfar, Luisa Knappe, Nicola Bianchetto Wolf, Genti Xhepa, Adrien Gleyzolle, Alexis Ricoeur, Valentina Garibotto, Ismini Mainta, Habib Zaidi","doi":"10.1007/s11307-025-01992-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>We evaluate the role of radiomics, dosiomics, and dose-volume constraints (DVCs) in predicting the response of hepatocellular carcinoma to selective internal radiation therapy with <sup>90</sup>Y with glass microspheres.</p><p><strong>Methods: </strong><sup>99m</sup>Tc-macroagregated albumin (<sup>99m</sup>Tc-MAA) and <sup>90</sup>Y SPECT/CT images of 17 patients were included. Tumor responses at three months were evaluated using modified response evaluation criteria in solid tumors criteria and patients were categorized as responders or non-responders. Dosimetry was conducted using the local deposition method (Dose) and biologically effective dosimetry. A total of 264 DVCs, 321 radiomic features, and 321 dosiomic features were extracted from the tumor, normal perfused liver (NPL), and whole normal liver (WNL). Five different feature selection methods in combination with eight machine learning algorithms were employed. Model performance was evaluated using area under the AUC, accuracy, sensitivity, and specificity.</p><p><strong>Results: </strong>No statistically significant differences were observed between neither the dose metrics nor radiomicas or dosiomics features of responders and non-responder groups. <sup>90</sup>Y-dosiomics models with any given set of inputs outperformed other models. This was also true for <sup>90</sup>Y-radiomics from SPECT and SPECT-clinical features, achieving an AUC, accuracy, sensitivity, and specificity of 1. Among MAA-dosiomic and radiomic models, two models showed AUC ≥ 0.91. While the performance of MAA-dose volume histogram (DVH)-based models were less promising, the <sup>90</sup>Y-DVH-based models showed strong performance (AUC ≥ 0.91) when considered independently of clinical features.</p><p><strong>Conclusion: </strong>This study demonstrated the potential of <sup>99m</sup>Tc-MAA and <sup>90</sup>Y SPECT-derived radiomics, dosiomics, and dosimetry metrics in establishing predictive models for tumor response.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11307-025-01992-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: We evaluate the role of radiomics, dosiomics, and dose-volume constraints (DVCs) in predicting the response of hepatocellular carcinoma to selective internal radiation therapy with 90Y with glass microspheres.
Methods: 99mTc-macroagregated albumin (99mTc-MAA) and 90Y SPECT/CT images of 17 patients were included. Tumor responses at three months were evaluated using modified response evaluation criteria in solid tumors criteria and patients were categorized as responders or non-responders. Dosimetry was conducted using the local deposition method (Dose) and biologically effective dosimetry. A total of 264 DVCs, 321 radiomic features, and 321 dosiomic features were extracted from the tumor, normal perfused liver (NPL), and whole normal liver (WNL). Five different feature selection methods in combination with eight machine learning algorithms were employed. Model performance was evaluated using area under the AUC, accuracy, sensitivity, and specificity.
Results: No statistically significant differences were observed between neither the dose metrics nor radiomicas or dosiomics features of responders and non-responder groups. 90Y-dosiomics models with any given set of inputs outperformed other models. This was also true for 90Y-radiomics from SPECT and SPECT-clinical features, achieving an AUC, accuracy, sensitivity, and specificity of 1. Among MAA-dosiomic and radiomic models, two models showed AUC ≥ 0.91. While the performance of MAA-dose volume histogram (DVH)-based models were less promising, the 90Y-DVH-based models showed strong performance (AUC ≥ 0.91) when considered independently of clinical features.
Conclusion: This study demonstrated the potential of 99mTc-MAA and 90Y SPECT-derived radiomics, dosiomics, and dosimetry metrics in establishing predictive models for tumor response.
期刊介绍:
Molecular Imaging and Biology (MIB) invites original contributions (research articles, review articles, commentaries, etc.) on the utilization of molecular imaging (i.e., nuclear imaging, optical imaging, autoradiography and pathology, MRI, MPI, ultrasound imaging, radiomics/genomics etc.) to investigate questions related to biology and health. The objective of MIB is to provide a forum to the discovery of molecular mechanisms of disease through the use of imaging techniques. We aim to investigate the biological nature of disease in patients and establish new molecular imaging diagnostic and therapy procedures.
Some areas that are covered are:
Preclinical and clinical imaging of macromolecular targets (e.g., genes, receptors, enzymes) involved in significant biological processes.
The design, characterization, and study of new molecular imaging probes and contrast agents for the functional interrogation of macromolecular targets.
Development and evaluation of imaging systems including instrumentation, image reconstruction algorithms, image analysis, and display.
Development of molecular assay approaches leading to quantification of the biological information obtained in molecular imaging.
Study of in vivo animal models of disease for the development of new molecular diagnostics and therapeutics.
Extension of in vitro and in vivo discoveries using disease models, into well designed clinical research investigations.
Clinical molecular imaging involving clinical investigations, clinical trials and medical management or cost-effectiveness studies.